Rifabutin analogs for the treatment of disease

The compound of any of the preceding claims, wherein X1 is independently selected from —C1-C5 alkyl, —C5-C6 cycloalkyl, —C1-C2 alkylene-(C5-C6 cycloalkyl), 5- to 6-membered heterocycloalkyl, —C1-C2 alkylene-(5- to 6-membered heterocycloalkyl), —C6-C10 aryl, —C1-C6 alkylene-(C6-C10 aryl), and 5- to 6-membered heteroaryl;

• wherein said alkyl is optionally substituted with one to three R1, preferably with exactly one R1;
• said cycloalkyl is each unsubstituted;
• said heterocycloalkyl is each independently, at each occurrence, optionally substituted with one or two R3;
• said aryl is each independently, at each occurrence, optionally substituted with one to three R4, preferably with exactly one R4;
• R1 is independently, at each occurrence, selected from —NR6R7 and —NHSO2R8;
• R3 is oxo;
• R4 is independently, at each occurrence, selected from —OC1-C6 alkyl, —NH2, and —NO2;
• R6 and R7 are independently, at each occurrence, selected from —H, —CH3, and —CH2—C6H5;
• and
• R8 is —CH3 or phenyl, wherein said phenyl is optionally substituted with one or more —CH3 or —C1.

The compound of any of the preceding claims, wherein X1 is independently selected from —C1-C3 alkyl, cyclohexyl, —C1 alkylene-(cyclohexyl), phenyl, —C1-C3 alkylene-(phenyl), and 2-pyridinyl;

• wherein said alkyl is optionally substituted with one or two R1, preferably with exactly one R1;
• said cyclohexyl is each unsubstituted;
• said phenyl each is unsubstituted or substituted with one or two, preferably with exactly one —OCH3 or —NO2;
• said 2-pyridinyl is unsubstituted;
• R1 is independently, at each occurrence, selected from —N(CH3)(CH2C6H5), and —NHSO2R8;
• and
• R8 is phenyl, wherein said phenyl is optionally substituted at the 4-position with —CH3 or —C1.